These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 36462464)
21. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034 [TBL] [Abstract][Full Text] [Related]
22. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. Javle M; King G; Spencer K; Borad MJ Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492 [TBL] [Abstract][Full Text] [Related]
23. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. Wu Q; Ellis H; Siravegna G; Michel AG; Norden BL; Fece de la Cruz F; Balasooriya ER; Zhen Y; Silveira VS; Che J; Corcoran RB; Bardeesy N Clin Cancer Res; 2024 Jan; 30(1):198-208. PubMed ID: 37843855 [TBL] [Abstract][Full Text] [Related]
37. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920 [TBL] [Abstract][Full Text] [Related]
38. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751 [TBL] [Abstract][Full Text] [Related]
39. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. Lee H; Wang K; Johnson A; Jones DM; Ali SM; Elvin JA; Yelensky R; Lipson D; Miller VA; Stephens PJ; Javle M; Ross JS J Clin Pathol; 2016 May; 69(5):403-8. PubMed ID: 26500333 [TBL] [Abstract][Full Text] [Related]
40. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. King G; Javle M Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]